Heres how different groups responded to treatment: Race and Ethnicity : Clinical benefits were consistent across all racial and ethnic groups Type 2 Diabetes : Patients without diabetes achieved higher total body weight loss (16.9%) versus those with diabetes (9.9%) at 12 months Body Mass Index (BMI) : After two years of treatment, 52.4% of participants moved down at least one BMI category Results show that 12% of adults receiving semaglutide reached a healthy BMI of 25 kg/m or less, compared to only 1.2% in the placebo group
As a new generation of long-acting GLP-1 receptor agonist, Semaglutide has shown good clinical advantages in reducing blood glucose, weight loss, cardiovascular benefits and safety
La AEMPS informa de una reaccin adversa ocular muy infrecuente en pacientes tratados con semaglutida
Your body preferentially breaks down fat when given a strong muscle-building signal through exercise and adequate amino acid availability
According to the Saxenda SmPC, the most frequently reported side effects include nausea (occurring in more than 1 in 10 patients), diarrhoea, constipation, vomiting, and headache